Breaking News Instant updates and real-time market news.

BIIB

Biogen

$311.59

-1.44 (-0.46%)

, IONS

Ionis Pharmaceuticals

$36.03

-0.61 (-1.66%)

09:08
10/04/16
10/04
09:08
10/04/16
09:08

Biogen could rise $20 or more per share on SMA success, says RBC Capital

RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

BIIB

Biogen

$311.59

-1.44 (-0.46%)

IONS

Ionis Pharmaceuticals

$36.03

-0.61 (-1.66%)

  • 26

    Oct

  • 06

    Nov

BIIB Biogen
$311.59

-1.44 (-0.46%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
IONS Ionis Pharmaceuticals
$36.03

-0.61 (-1.66%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.

TODAY'S FREE FLY STORIES

TGT

Target

$66.91

0.4 (0.60%)

, AZO

AutoZone

$740.85

8.1 (1.11%)

20:25
02/27/17
02/27
20:25
02/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.91

0.4 (0.60%)

AZO

AutoZone

$740.85

8.1 (1.11%)

DPZ

Domino's Pizza

$185.42

-0.86 (-0.46%)

VRX

Valeant

$16.71

0.53 (3.28%)

PAH

Platform Specialty Products

$13.30

0.25 (1.92%)

ENDP

Endo

$13.29

0.14 (1.06%)

DDD

3D Systems

$16.94

0.45 (2.73%)

SEAS

SeaWorld

$18.78

0.16 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

CSCO

Cisco

$34.26

-0.06 (-0.17%)

20:04
02/27/17
02/27
20:04
02/27/17
20:04
Hot Stocks
Cisco says signs three-year services agreement with Saudi Telecom »

At Mobile World Congress,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

YHOO

Yahoo

$45.71

0.16 (0.35%)

, VZ

Verizon

$49.94

-0.66 (-1.30%)

20:01
02/27/17
02/27
20:01
02/27/17
20:01
Hot Stocks
Yahoo responds to Senate information request on cybersecurity breaches »

Responding to a February…

YHOO

Yahoo

$45.71

0.16 (0.35%)

VZ

Verizon

$49.94

-0.66 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:38
02/27/17
02/27
19:38
02/27/17
19:38
Hot Stocks
Priceline: 'Solid start' to Q1, shift of Easter into Q2 to pressure some metrics »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ROYT

Pacific Coast Oil

$1.94

0.02 (1.04%)

19:33
02/27/17
02/27
19:33
02/27/17
19:33
Downgrade
Pacific Coast Oil rating change  »

Pacific Coast Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

, BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

19:28
02/27/17
02/27
19:28
02/27/17
19:28
Hot Stocks
Court rules in favor of Arctic Cat in Bombardier patent litigation »

Arctic Cat (ACAT)…

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:17
02/27/17
02/27
19:17
02/27/17
19:17
Hot Stocks
Priceline CFO: 'Hopeful' on promised Trump tax reform »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:16
02/27/17
02/27
19:16
02/27/17
19:16
Hot Stocks
Priceline says board approved new $2B buyback authorization »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

19:09
02/27/17
02/27
19:09
02/27/17
19:09
Hot Stocks
vTv Therapeutics sees reporting topline data from STEADFAST Part A in early 2018 »

Says STEADFAST Part B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:55
02/27/17
02/27
18:55
02/27/17
18:55
Earnings
AAC Holdings sees FY17 adjusted EPS 50c-58c, consensus 72c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CSX

CSX

$48.71

0.23 (0.47%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
CSX sees at least $160M charge from 'management streamlining' plan »

CSX disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$76.45

0.15 (0.20%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
Iowa American Water rate adjustment approved by IUB »

Following a 10-month…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:53
02/27/17
02/27
18:53
02/27/17
18:53
Hot Stocks
AAC Holdings sees over $8M in savings in 2017 from workforce reduction »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MORN

Morningstar

$81.62

-0.1 (-0.12%)

18:52
02/27/17
02/27
18:52
02/27/17
18:52
Hot Stocks
Morningstar CFO Stephane Biehler to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$248.60

3.55 (1.45%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Hot Stocks
Northrop Grumman appoints Pamiljans as aerospace systems president »

The board of Northrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Earnings
AAC Holdings reports Q4 adjusted EPS 15c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MS

Morgan Stanley

$45.84

0.31 (0.68%)

18:48
02/27/17
02/27
18:48
02/27/17
18:48
Hot Stocks
Morgan Stanley discloses erroneous client tax reporting, says in talks with IRS »

Morgan Stanley disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

MS

Morgan Stanley

$45.84

0.31 (0.68%)

, BK

BNY Mellon

$47.11

0.02 (0.04%)

18:47
02/27/17
02/27
18:47
02/27/17
18:47
Hot Stocks
Morgan Stanley says reached settlement in New York Mellon dispute »

Morgan Stanley (MS)…

MS

Morgan Stanley

$45.84

0.31 (0.68%)

BK

BNY Mellon

$47.11

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

OLN

Olin Corp.

$30.90

0.1 (0.32%)

18:41
02/27/17
02/27
18:41
02/27/17
18:41
Hot Stocks
Olin Corp. chairman Joseph Rupp to retire »

Olin Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 14

    Mar

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:35
02/27/17
02/27
18:35
02/27/17
18:35
Hot Stocks
Wheeler REIT revises dividend payment schedule »

Effective April 1, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:34
02/27/17
02/27
18:34
02/27/17
18:34
Hot Stocks
Ashford Hospitality: FelCor statements on proposal 'misguided and misleading' »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Ashford Hospitality Trust acknowledges Land and Buildings endorsement »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Wheeler REIT announces 1-for-8 reverse stock split »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

18:18
02/27/17
02/27
18:18
02/27/17
18:18
Earnings
vTv Therapeutics reports Q4 EPS (42c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:10
02/27/17
02/27
18:10
02/27/17
18:10
Hot Stocks
Delek Logistics targets 10% annual increase in distribution through 2019 »

CEO Yemin concluded,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.